News
Helgi Kormaksson Joins CTS Executive Team SAN FRANCISCO, CA / ACCESS Newswire / June 6, 2025 / CTS is excited to announce that Helgi Kormaksson has joined the company as Chief Design Officer. Helgi ...
The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...
5h
Zacks Investment Research on MSNIs Novo Nordisk's Next Generation Obesity Pipeline a Game Changer?Novo Nordisk NVO has seen strong momentum in recent years, driven by the commercial success of its blockbuster semaglutide ...
In the past, studies in type-2 diabetes patients have linked Ozempic to the condition called non-arteritic anterior ischemic ...
We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...
Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...
The standard of care for managing patients with type 2 diabetes and CKD -- in addition to a healthy lifestyle -- has always ...
Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...
Adding an SGLT2 inhibitor to finerenone in CKD and type 2 diabetes yields “remarkable” albuminuria reductions that may, if ...
More American teenagers now use the weight-loss drug Wegovy, as doctors and families grow more comfortable with the treatment ...
Long Islanders, doctors and industry experts weigh in on medicines like Ozempic and Wegovy — how they work, what they ...
During the most recent episode of Mad Money, Jim Cramer opened the show by emphasizing just how much American companies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results